Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Cancers|May 28, 2020
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR TherapyRiccardo Giampieri, Pina Ziranu, Bruno Daniele, et al.
Cancer Chemotherapy and Pharmacology|September 8, 2019
Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancerGerardo Rosati, Raffaele Addeo, Giuseppe Aprile, et al.
Nature Communications|March 25, 2026
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trialAngela Damato, Riziero Esposito Abate, Simona Tessitore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal CancerTimothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.
Cancer Medicine|October 18, 2016
Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr StudyCarmine Pinto, Francesca Di Fabio, Gerardo Rosati, et al.
Cancers|February 25, 2022
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal AntibodiesAnna Maria Rachiglio, Laura Forgione, Raffaella Pasquale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2024
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The IMPROVE TrialAntonio Avallone, Francesco Giuliani, Alfonso De Stefano, et al.
JAMA Network Open|July 26, 2021
Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical TrialAntonio Avallone, Maria C Piccirillo, Guglielmo Nasti, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Sara Lonardi, Fabio Galli, et al.
Future Oncology (London, England)|October 5, 2017
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enoughLorenzo Fornaro, Valentina Fanotto, Gianna Musettini, et al.
Pageof 9